Clinical trial NCT04497116: Study of RP-3500, Camonsertib, in Advanced Solid Tumors
Official title: Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumor
Keywords: Adult
Lead sponsor: Repare Therapeutics
Sponsor class: INDUSTRY
First posted: 2020-08-04
Enrollment: 285
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Dose Escalation, expansion and phase 2
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a PARP inhibitor, or Gemcitabine in patients with advanced solid tumors with ATR inhibitor-sensitizing mutations. This study will also evaluate the safety and tolerability of RP-3500 (camonsertib) alone or in combination with talazoparib or gemcitabine, examine both the pharmacokinetics (PK)and pharmacodynamics (PD)and investigate its anti-tumor activity in solid tumors.

Detailed description: This is a first-in-human, Phase 1/2a, multi-center, open-label, dose-escalation and expansion study to:

* Evaluate the safety profile and MTD of RP-3500 (camonsertib) when administered orally, alone and in combination with talazoparib or gemcitabine, to establish the dose and schedule recommended for the Phase 2
* Characterize the PK profile of RP-3500 (camonsertib) alone or in combination with talazoparib or gemcitabine
* Identify anti-tumor activity associated with RP-3500 (camonsertib) given alone or in combination with talazoparib or gemcitabine
* Examine biomarker responses and establish a correlation with RP-3500 (camonsertib) exposure and clinical outcomes.

The initial cohorts will test RP-3500 (camonsertib) as monotherapy. Additional cohorts will enroll with RP-3500 (camonsertib) in combination with talazoparib or gemcitabine.

After the RP2D and schedule is determined, expansion cohort(s) for RP-3500 (camonsertib) will be enrolled to study the anti-tumor effect, and further examine the safety and PK of RP-3500 (camonsertib) at the RP2D

Eligibility criteria: Inclusion Criteria:

* Written informed consent, according to local guidelines, signed and dated by the patient or legal guardian prior to the performance of any study-specific procedures, sampling, or analyses.
* Male or female and ≥ 18 years-of-age at the time of signature of the consent.
* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
* Histologically confirmed solid tumors resistant or refractory to standard treatment and/or patients who are intolerant to standard therapy.
* Measurable disease as per RECIST v1.1
* Existing biomarker profile (tumor tissue or plasma) reported from a local test obtained in a certified lab per institutional guidelines:
* Available tumor tissue
* Ability to comply with the protocol and study procedures detailed in the Schedule of Assessments.
* Ability to swallow and retain oral medications.
* Acceptable organ function at screening
* Acceptable blood counts at screening
* Negative pregnancy test (serum or urine) for females of childbearing potential at Screening and prior to first study drug.
* Resolution of all toxicities of prior treatment or surgery.
* Male patients with female partners of childbearing potential and females of childbearing potential must follow a contraception method (oral contraceptives allowed) during their participation in the study and for at least 6 months following last dose of study drug. Male patients must also refrain from donating sperm during their participation in the study and for 6 months following last dose of study drug.

Exclusion Criteria:

* Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 14 days prior to first dose of study drug.
* History or current condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
* Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.
* Known hypersensitivity to any of the ingredients of RP-3500 (camonsertib).
* Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the patient's safety.
* Uncontrolled, symptomatic brain metastases.
* Uncontrolled high blood pressure
* Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
* Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).
* History or presence of an abnormal ECG that is clinically significant in the investigator's opinion.
* History of ventricular dysrhythmias or risk factors such as structural heart disease, coronary heart disease (clinically significant electrolyte abnormalities or family history of sudden unexplained death or long QT syndrome
* Current treatment with medications that are well-known to prolong the QT interval
* History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis

Primary outcomes:
measure: To define the Maximum Tolerated Dose (MTD) which will then be used to inform and determine the Recommended Phase 2 Dose (RP2D) and schedule alone or in combination with talazoparib or gemcitabine
timeFrame: Up to 90 days after last administration of study intervention
measure: Frequency of Dose limiting Toxicities (DLTs)
timeFrame: At the end of cycle 1 (each cycle is 21 days or 28 days)
measure: Safety and tolerability
timeFrame: Up to 90 days after last administration of study intervention
Secondary outcomes:
measure: Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1) or confirmed response in CA-125 or PSA per GCIG or PSWG criteria.
timeFrame: About 1 year
measure: Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1)
timeFrame: About 1 year
measure: Assess CR+PR+SD (≥ 4 months) based on RECIST v1.1, confirmed CA-125 response by GCIG criteria, or PSA response based on PCWG3
timeFrame: About 1 year
measure: Assess preliminary anti-tumor activity with Duration of Response (DOR) in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1).
timeFrame: About 1 year
measure: Characterize the pharmacokinetic profile of RP-3500 (camonsertib)
timeFrame: Through Study Day 152
measure: Peak plasma concentration
timeFrame: Through Study Day 152
measure: To assess PK parameters of RP-3500 (camonsertib) monotherapy in fasted and fed states
timeFrame: Through Study Day 152
measure: Pharmacodynamic biomarkers of DNA damage (e.g. gH2AX) will be measured by immunohistochemistry and the percentage of positive cells will be compared between the pre and post treatment biopsies to evaluate target engagement
timeFrame: Through Study Day -28 to Day 66 (each cycle is 21 days)
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Participating Site 1014
state: Illinois
city: Boston
country: United States
facility: Participating Site 1006
state: Massachusetts
city: Boston
country: United States
facility: Participating Site 1002
state: Massachusetts
city: New York
country: United States
facility: Participating Site 1004
state: New York
city: Durham
country: United States
facility: Participating Site 1005
state: North Carolina
city: Providence
country: United States
facility: Participating Site 1007
state: Rhode Island
city: Nashville
country: United States
facility: Participating Site 1003
state: Tennessee
city: Houston
country: United States
facility: Participating Site 1001
state: Texas
city: Toronto
country: Canada
facility: Participating Site 2001
state: Ontario
city: Copenhagen
country: Denmark
facility: Participating Site 4001
state: DK
city: London
country: United Kingdom
facility: Participating Site 3003
city: Manchester
country: United Kingdom
facility: Participating Site 3001
city: Newcastle Upon Tyne
country: United Kingdom
facility: Participating Site 3002
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Timothy A Yap, MBBS PhD FRCP
role: PRINCIPAL_INVESTIGATOR
References: